CD47-targeted therapies, including mAbs, small molecule inhibitors, and nanotherapeutics, have been developed to block the CD47-SIRPα interaction and enhance phagocytosis of cancer cells by myeloid cells, thereby promoting anti-tumor immunity (Fig. 1) [50,51]. This evidence concerns the gene CD47 and neoplasm.